CardiAMP Cell Therapy

About BioCardia

BioCardia's mission is to advance cardiovascular regenerative medicine through its targeted, minimally invasive delivery platforms. Its core achievement is the development of the Helix™ transendocardial delivery system, which has been used in multiple clinical trials for heart failure. The company's strategy is twofold: advancing its own autologous cell therapy programs while actively seeking partnerships to deploy its delivery technology with third-party therapeutics. Despite its innovative approach, BioCardia operates as a micro-cap company facing significant financial and execution challenges.

About BioCardia

BioCardia's mission is to advance cardiovascular regenerative medicine through its targeted, minimally invasive delivery platforms. Its core achievement is the development of the Helix™ transendocardial delivery system, which has been used in multiple clinical trials for heart failure. The company's strategy is twofold: advancing its own autologous cell therapy programs while actively seeking partnerships to deploy its delivery technology with third-party therapeutics. Despite its innovative approach, BioCardia operates as a micro-cap company facing significant financial and execution challenges.

Therapeutic Areas